RVMDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMDW
Revolution Medicines, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$182.15+4.19 (+2.35%)
Close on Oct 19, 2026
- Market cap
- $38.41B
- P/E (TTM)
- –
- Dividend yield
- –
Revolution Medicines statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Revolution Medicines | Industry median |
|---|---|---|
| Market Cap | $39.04B | $164.85M |
| Enterprise Value | $35.10B | $87.06M |
| PB Ratio | 14.98 | 2.03 |
| P/TBV Ratio | 15.40 | 2.31 |
Income (trailing twelve months)
| Measure | Revolution Medicines | Industry median |
|---|---|---|
| Operating Income | -$1.63B | -$21.44M |
| Pretax Income | -$1.77B | -$14.45M |
| Net Income | -$1.77B | -$22.46M |
| EBITDA | -$1.62B | -$16.91M |
| EPS (Diluted) | -$8.84 | -$0.83 |
Returns
| Measure | Revolution Medicines | Industry median |
|---|---|---|
| Return on Equity (ROE) | -79.1% | -53.1% |
| Return on Assets (ROA) | -52.4% | -41.0% |
| Return on Capital Employed (ROCE) | -41.0% | -37.8% |
Balance sheet
| Measure | Revolution Medicines | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $3.94B | $62.42M |
| Net Cash (Debt) | $3.94B | $15.68M |
| Net Cash Per Share | $18.37 | $0.66 |
| Equity (Book Value) | $2.61B | $48.79M |
| Book Value Per Share | $12.16 | $1.36 |
| Tangible Book Value | $2.54B | $23.06M |
| Working Capital | $3.67B | $75.77M |
Financial position
| Measure | Revolution Medicines | Industry median |
|---|---|---|
| Current Ratio | 11.38 | 3.30 |
| Quick Ratio | 11.12 | 2.39 |
| Interest Coverage | -27.42 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Revolution Medicines | Industry median |
|---|---|---|
| Operating Cash Flow | -$1.22B | -$12.35M |
| Capital Expenditures | -$9.10M | -$1.06M |
| Free Cash Flow | -$1.23B | -$20.28M |
| FCF Per Share | -$5.75 | -$0.42 |
Efficiency
| Measure | Revolution Medicines | Industry median |
|---|---|---|
| Profits Per Employee | -$2.00M | -$703.34K |
| Employee Count | 883 | 74 |
Dividends and yields
| Measure | Revolution Medicines | Industry median |
|---|---|---|
| Earnings Yield | -4.53% | -22.7% |
| FCF Yield | -3.16% | -9.07% |
Shares
| Measure | Revolution Medicines | Industry median |
|---|---|---|
| Shares Outstanding | 214,336,000 | 58,179,650 |
| Shares Change (YoY) | 10.4% | 11.1% |
| Shares Change (QoQ) | 7.03% | 0.54% |
| Float | 202,951,000 | 49,173,100 |
| Shares Held by Insiders | 5.31% | 11.6% |
| Shares Held by Institutions | 104.6% | 59.4% |
Scores
| Measure | Revolution Medicines | Industry median |
|---|---|---|
| Altman Z-Score | 12.14 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Revolution Medicines's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.